Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aligos Therapeutics Inc ALGS

Healthcare Biotechnology
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug... see more

Recent & Breaking News (NDAQ:ALGS)

Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver's International Liver Congress(TM) 2022

GlobeNewswire May 3, 2022

Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022

GlobeNewswire April 27, 2022

Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development

GlobeNewswire April 4, 2022

Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio

GlobeNewswire March 22, 2022

Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

GlobeNewswire March 10, 2022

Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022

GlobeNewswire March 2, 2022

Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 3, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS

Newsfile February 2, 2022

SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders

Business Wire January 28, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS

PR Newswire January 27, 2022

Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)

GlobeNewswire January 26, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS

Newsfile January 25, 2022

ALIGOS ALERT: Bragar Eagel & Squire, P.C. is Investigating Aligos Therapeutics, Inc. on Behalf of Aligos Stockholders and Encourages Investors to Contact the Firm

Business Wire January 21, 2022

SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders

Business Wire January 20, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS

Newsfile January 19, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS

PR Newswire January 17, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS

Newsfile January 11, 2022

Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH

GlobeNewswire January 11, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS

PR Newswire January 7, 2022

Aligos Halting Further Development of STOPS(TM) Drug Candidate, ALG-010133

GlobeNewswire January 6, 2022